CVL-871
| Clinical data | |
|---|---|
| Routes of administration | Oral administration |
| Drug class | Dopamine receptor agonist |
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][3] It is taken via oral administration.[1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.[1]
See also
- Tavapadon (CVL-751)
References
- 1 2 3 4 5 "CVL 871 - AdisInsight".
- 1 2 Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
- ↑ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
External links
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.